About Avicanna
Avicanna is a company based in Toronto (Canada) founded in 2016 by Aras Azadian. Avicanna has raised $5.94 million across 19 funding rounds from investors including Tasly, Orthogonal Thinker and Barn Invest. The company has 55 employees as of December 31, 2024. Avicanna offers products and services including Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients. Avicanna operates in a competitive market with competitors including ZYUS Life Sciences, Sanity Group, Terraflos, Little Green Pharma and IMCannabis, among others.
- Headquarter Toronto, Canada
- Employees 55 as on 31 Dec, 2024
- Founders Aras Azadian
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avicanna Inc
-
Annual Revenue
$17.7 M (USD)51.62as on Dec 31, 2024
-
Net Profit
-$2.35 M (USD)57.19as on Dec 31, 2024
-
EBITDA
-$2.16 M (USD)54.95as on Dec 31, 2024
-
Total Equity Funding
$5.94 M (USD)
in 19 rounds
-
Latest Funding Round
$220.35 K (USD), Post-IPO
Feb 10, 2026
-
Investors
Tasly
& 2 more
-
Employee Count
55
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Avicanna
Avicanna is a publicly listed company on the TSX with ticker symbol AVCN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Avicanna
Avicanna offers a comprehensive portfolio of products and services, including Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients.
Evidence-based cannabinoid formulations for medical use.
Developing cannabinoid-based drugs for health applications.
Cannabinoid ingredients for commercial pharmaceutical products.
People of Avicanna
Unlock access to complete
Unlock access to complete
Funding Insights of Avicanna
Avicanna has successfully raised a total of $5.94M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $220.35 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Post-IPO — $220,347
-
First Round
First Round
(26 May 2017)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2026 | Amount | Post-IPO - Avicanna | Valuation |
investors |
|
| Jul, 2025 | Amount | Post-IPO - Avicanna | Valuation |
investors |
|
| Nov, 2024 | Amount | Post-IPO - Avicanna | Valuation |
investors |
|
Investors in Avicanna
Avicanna has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Tasly, Orthogonal Thinker and Barn Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm & investment bank focused on plant science based companies
|
Founded Year | Domain | Location | |
|
Barn Invest is focused on greentech investments in Latin America.
|
Founded Year | Domain | Location | |
|
Traditional Chinese medicines are manufactured and distributed globally.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Avicanna
Financial Statements - Avicanna
Avicanna Comparisons
Competitors of Avicanna
Avicanna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZYUS Life Sciences, Sanity Group, Terraflos, Little Green Pharma and IMCannabis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cannabis-derived therapeutics for multiple indications are developed.
|
|
| domain | founded_year | HQ Location |
Developer of cannabinoid-based pharmaceuticals and well-being products
|
|
| domain | founded_year | HQ Location |
Medical cannabis products are provided based on GMP processes.
|
|
| domain | founded_year | HQ Location |
Manufacturer of medicinal cannabis for therapeutic use
|
|
| domain | founded_year | HQ Location |
Developer of medical cannabis products
|
Frequently Asked Questions about Avicanna
Avicanna was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Avicanna is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Aras Azadian is the current CEO of Avicanna. They have also founded this company.
Avicanna is a funded company, having raised a total of $5.94M across 19 funding rounds to date. The company's 1st funding round was a Post-IPO of $573.25K, raised on May 26, 2017.
As of Dec 31, 2024, the latest employee count at Avicanna is 55.
Annual revenue of Avicanna is $17.7M as on Dec 31, 2024.
Avicanna was founded in 2016 in Toronto, Canada, as a developer in the cannabinoid sector. Advanced formulations and delivery systems based on plant-derived cannabinoids are created for medical applications and consumer goods. Solutions are marketed through channels such as derma-cosmetics, phytotherapeutics, and pharmaceuticals, targeting diverse markets with a focus on therapeutic and wellness products.
Avicanna's top competitors include ZYUS Life Sciences, Neocannbio and IMCannabis.
Avicanna offers Medical Cannabis Products, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients.
Yes, Avicanna is publicly traded on TSX under the ticker symbol AVCN.
Avicanna has 3 investors. Key investors include Tasly, Orthogonal Thinker, and Barn Invest.
The ticker symbol of Avicanna is AVCN on TSX.